Compounded semaglutide check-ins: what TikTok gets right and wrong

What's this video probably claiming?

Based on the caption and hashtags, this is almost certainly a personal progress update from someone using compounded semaglutide for weight loss. These videos follow a pretty predictable format: the creator shares how much weight they've lost, how the medication is making them feel, and possibly their current dose or injection routine. The #compoundsemaglutide hashtag is a tell, because it signals the person is using a version made by a compounding pharmacy rather than the brand-name Ozempic or Wegovy. With 18.9K views, this has enough reach to shape real expectations. The implicit claims are usually optimistic: compounded semaglutide works just like the brand-name version, the side effects are manageable, and the weight loss is dramatic and fast. Whether any of that holds up depends on which parts of the story are being told.

What does the science actually show?

The clinical evidence for semaglutide as a weight loss agent is genuinely strong. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on 2.4mg weekly subcutaneous semaglutide lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. That's a real effect, not a marginal one. The STEP 4 trial (Rubino et al., 2021, JAMA) added an important caveat: people who stopped semaglutide regained about two-thirds of the weight they lost within a year. Nausea was the most commonly reported side effect, affecting roughly 44% of participants. These are the numbers worth knowing. Personal check-in videos typically capture only the early, often more dramatic phase of weight loss, which does not represent the full trajectory most users will experience.

Where does the social media noise diverge from clinical reality?

Several things go reliably wrong in the compounded semaglutide conversation on TikTok. First, creators frequently imply that compounded semaglutide is equivalent to FDA-approved Ozempic or Wegovy. The FDA has been explicit that it has not evaluated compounded semaglutide products for safety, efficacy, or quality. In March 2024, the FDA flagged reports of dosing errors and adverse events associated with compounded versions, some of which used semaglutide salt forms rather than the base form used in approved products. Second, individual progress videos create selection bias. People posting dramatic results at week eight are not representative of average outcomes, dropout rates, or what happens when insurance doesn't cover the cost (brand Wegovy lists above $1,300 per month). Third, side effect profiles are routinely soft-pedaled in these formats, and the cardiovascular contraindications, pancreatitis risk, and thyroid tumor signals from rodent studies rarely make it into the caption.

What should you actually know?

If you're watching these videos and considering compounded semaglutide, here is what the clinical picture actually looks like. The active ingredient in approved semaglutide products is semaglutide base. Some compounders use sodium or acetate salt forms, which have different molecular weights and unknown bioequivalence profiles. The FDA's shortage designation that temporarily allowed compounding of semaglutide was officially resolved for Wegovy in February 2025, meaning many compounders no longer operate in a regulatory safe harbor. Real-world efficacy data outside clinical trials, from sources like Rosenstock et al. (2023, Diabetes Care), suggests outcomes are meaningful but more variable than trial populations imply. Weight loss is not linear, plateaus are common after months three through six, and the medication requires ongoing use to maintain results. A personal check-in video at any single time point tells you almost nothing about long-term outcomes.